Site-Specific Resolution of Enthesitis in Patients With Axial Spondyloarthritis Treated With Tumor Necrosis Factor Inhibitors

Michael John Nissen (michael.j.nissen@hcuge.ch)  
Hôpitaux Universitaires de Genève Service de Rhumatologie  https://orcid.org/0000-0002-6326-1764

Burkhard Möller  
Inselspital University Hospital Bern: Inselspital Universitatsspital Bern

Adrian Ciurea  
University of Zurich: Universität Zurich

Ruediger Mueller  
Kantonsspital Aarau AG

Patrick Zueger  
AbbVie Inc

Martin Schulz  
AbbVie AG

Fabiana Ganz  
AbbVie AG

Almut Scherer  
SCQM

Eleftherios Papagiannoulis  
SCQM

Thomas Hügle  
CHUV: Centre Hospitalier Universitaire Vaudois

Research article

Keywords: axial spondyloarthritis, enthesitis, resolution, tumor necrosis factor inhibitors

DOI: https://doi.org/10.21203/rs.3.rs-115375/v1

License: Creative Commons Attribution 4.0 International License. Read Full License
Abstract

**Background:** Enthesitis is a hallmark of spondyloarthritis (SpA) with substantial impact on quality of life. Reports of treatment effectiveness across individual enthesitis sites in real-world patients with axial SpA (axSpA) are limited. We investigated the evolution of enthesitis following tumour necrosis factor inhibitor (TNFi) initiation in axSpA patients, cumulatively and at specific axial and peripheral sites.

**Methods:** AxSpA patients in the Swiss Clinical Quality Management Registry were included if they initiated a TNFi, had an available Maastricht Ankylosing Spondylitis Enthesitis Score, modified to include the plantar fascia (mMASES, 0–15), at start of treatment and after 6 and/or 12 months and ≥12 months follow-up. Logistic regression models were utilized to analyze explanatory variables for enthesitis resolution.

**Results:** Overall, 1668 TNFi treatment courses (TCs) were included, of which 1117 (67%) had active enthesitis at baseline. Reduction in mMASES at the 6- and 12-month time points was experienced in 72% and 70% of TCs, respectively. Enthesitis resolution at 6/12 months occurred in 37.9% and 43.0% of all TNFi TCs and 40.7% and 50.9% of first TNFi TCs. At 6 months, a significant reduction in the frequency of enthesitis was observed at all sites, except for the Achilles tendon and plantar fascia among first TNFi TCs while at 12 months, reduction was significant at all sites in both TC groups. Enthesitis resolved in 60.3%–77% across anatomical sites, while new incident enthesitis occurred in 4.0%–13.5% of all TNFi TCs at 12 months. Both baseline and new-incident enthesitis occurred most frequently at the posterior superior iliac spine and the fifth lumbar spinous process. Younger age and lower mMASES at baseline were predictors of complete enthesitis resolution, while female sex and second- or later-line TNFi treatment were associated with persistence of enthesitis at 12 months.

**Conclusion:** In real-world axSpA patients treated with a TNFi, enthesitis improved in the majority of patients across all anatomical sites. Significant improvement at the Achilles and plantar fascia entheses was observed only at 12 months. Complete and site-specific enthesitis resolution occurred in ≥40% and ≥60% of TCs evaluated at 12 months, with a low incidence of new site-specific enthesitis.

**Trial registration:** not applicable

Introduction

Axial Spondyloarthritis (axSpA) is an inflammatory rheumatic disease with a diverse clinical presentation. [1, 2] AxSpA is characterized by excess bone formation that results in bone fusion and sclerosis of the sacroiliac joints and spine.[1–4] Chronic inflammatory back pain is the most common symptom of axSpA, and the associated pain, stiffness, and fatigue limit physical functioning and the ability to perform activities of daily living.[2, 5] Other musculoskeletal manifestations of axSpA include arthritis, dactylitis, and enthesitis.[1, 2] Extra-articular manifestations, such as acute anterior uveitis, psoriasis, and inflammatory bowel disease are also characteristic of axSpA.[1, 2] Consequently, axSpA carries a significant patient burden and has a substantial impact on patients’ quality of life.[1, 2, 5–8]
Enthesitis, defined as an inflammation of the tendon, ligament, and/or joint capsule insertions into bone, is reported in the majority of patients with spondyloarthritis (SpA)[9] and is recognized as the distinctive pathological process in SpA.[10, 11] Advanced imaging and studies in animal models and humans have shown that enthesitis is associated with diffuse effects on adjacent connective tissue and underlying bone structures.[11, 12] Pathophysiological mechanisms of enthesitis in SpA may include both mechanical and autoimmune features.[13, 14] Repeated biomechanical stress is thought to cause microdamage at the entheses, which in turn induces an inflammatory response in the adjacent synovial tissue leading to synovitis.[11, 13, 14] Enthesitis is associated with higher disease activity, more disability, work absenteeism, and a poorer quality of life in axSpA patients.[9]

Conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) have been used with some success to treat peripheral arthritis in SpA patients; however, they have not clearly demonstrated efficacy for the treatment of enthesitis or the axial manifestations of axSpA.[15–17] In contrast, tumour necrosis factor inhibitors (TNFi's) have been shown to be effective in improving or resolving enthesitis in clinical trials in patients with axSpA.[18–23] However, other clinical trials evaluating the benefit of TNFi's on enthesitis in axSpA did not demonstrate a significant improvement or reported results that varied by the assessment utilized.[24, 25] It is important to note that many of these studies tended to involve a rather small number of patients, with a low baseline prevalence of enthesitis and with enthesitis as a secondary outcome. Real-world data on the effectiveness of TNFi's for enthesitis in axSpA patients is even more limited. Moreover, data on enthesitis site-specific treatment effectiveness is rare, but required because the effectiveness of TNFi's on enthesitis may vary by enthesitis site and therefore vary depending on the enthesitis index utilized.[25] The objective of this analysis was to investigate the real-world treatment effectiveness of TNFi therapy on enthesitis, both cumulatively and at specific enthesitis locations, including the spine, thoracic cage, Achilles tendon, and the plantar fascia, in patients with axSpA initiating a TNFi.

**Methods**

**Study Design and Data Source**

This observational cohort study utilized prospectively collected data from the nationwide Swiss Clinical Quality Management in Rheumatic Diseases (SCQM) registry in inflammatory rheumatic diseases. This ongoing cohort of patients with ankylosing spondylitis/axSpA was established in 2005[26] and provides an integrated feedback system for rheumatologists and their patients to monitor disease activity, disability, and radiographic damage using standardized assessments.[27, 28] The patients included in the SCQM axSpA registry come from diverse clinical settings, including approximately 50% from private practice, 30% from non-academic centers, and 20% from academic centers.[26] At registry inclusion, demographic and disease characteristics, concomitant treatments, laboratory values, and comorbidities were collected by the treating rheumatologists.[26] Patients completed self-administered questionnaires to assess their disease state and quality of life.[26] Informed written consent was obtained from all
patients prior to inclusion in the SCQM registry, and a regional ethics committee (CER-VD, 2019–00278) provided approval for collection of patient data from the SCQM cohort.[26]

**Participants**

Included patients were ≥ 16 years of age with a diagnosis of axSpA, as determined by a consultant rheumatologist, and had initiated a TNFi after inclusion into the SCQM registry. Patients were required to have available enthesitis assessments (ie, modified MASES [mMASES]; modified to include the plantar fascia) at TNFi initiation ('baseline visit'; visits with a mMASES within 90 days prior to TNFi treatment initiation start date were considered valid), ≥ 1 enthesitis assessment available during the follow-up period, and a treatment course (TC) with ≥ 1 year of follow-up after treatment initiation. It was therefore possible for a single patient to contribute several TCs to the analysis. TCs with a particular TNFi (eg, with a change of dose or a brief pause in treatment) in the same patient were merged if they corresponded to the same TNFi and if the end of the last dose of the last TC was within a 90-day time window of the first dose of the next TC. The follow-up period for a TC was defined as the time interval between treatment initiation day until the latest of the following days: last recorded visit, last recorded treatment stop date, or last recorded treatment adjustment date. The TNFi’s considered in the analysis included adalimumab, etanercept, golimumab, certolizumab pegol, and infliximab.

**Outcomes**

The mMASES included the 13 sites of the MASES: 1st costochondral joints, 7th costochondral joints, iliac crests, anterior superior iliac spines, posterior superior iliac spines, insertion of Achilles tendons, and the 5th lumbar spinous process, as well as 2 additional sites, with inclusion of the plantar fascia insertion bilaterally, for a total of 15 sites (range, 0–15).[29] Among patients with presence of enthesitis at baseline (mMASES ≥ 1), both the resolution and reduction of the mMASES at 6-month and 12-month follow-ups were assessed overall and in the subset of TCs representing patients who were TNFi naïve at baseline (ie, first TNFi TC). Enthesitis localization frequencies at the 15 mMASES sites were examined at 6-month and at 12-month follow-ups.

**Statistical Analyses**

Among TCs in patients with enthesitis at baseline (mMASES ≥ 1), the proportion with complete enthesitis resolution, defined as patients with no enthesitis (mMASES=0), was measured at both the 6-and 12-month follow-up time points. Baseline demographic and clinical characteristics were analyzed using descriptive statistics, continuous variables were summarized as medians with IQR, and categorical variables as frequencies and percentages of patients. For enthesitis localization change, an intention to treat (ITT) approach was used whereby TCs were included regardless of whether the patient was still under the same treatment at 6 and/or 12 months. McNemar’s test or a Mid-ρ method (if counts in the contingency tables were <25) was used to compare the proportion of patients with enthesitis at each mMASES site between baseline and 6 or 12 months, and the resultant P values were corrected for multiplicity using the Holm-Bonferroni method (the correction was performed per set of comparisons for the 2 follow-up time points and P < 0.05 level of significance was utilized).
Multiple missing value imputation by chained equations (MICE) was performed for baseline covariates for all TNFi TCs. No evidence was found that any of the variables influenced the missingness distribution and a missing at random data pattern was assumed. Diagnostic measures were used to evaluate the convergence of the MICE algorithm. We utilized logistic regression in order to analyze the binary outcome of enthesitis resolution and odds ratios were derived. The analyses were performed with both MICE imputed data and complete case data.

**Results**

Of 3325 identified TCs in 2130 patients with axSpA who initiated TNFi therapy, 1668 TCs in 1393 patients met all 3 entry criteria of a mMASES available at baseline, at least another mMASES reported during follow-up, and available follow-up of at least 12 months (Fig. 1). Regarding the TCs, at baseline, the majority included men (53.1%), median age was 42 years (IQR, 33–51), median disease duration was 9 years (IQR, 4–18), and median Ankylosing Spondylitis Disease Activity Score (ASDAS-CRP) was 3.3 (IQR, 2.6–3.9) (Table 1). The median mMASES was 2 (IQR, 0–4) and 67% of TCs (1117 of 1668) were enthesitis positive (mMASES ≥ 1) at baseline; 23.5% were simultaneously co-treated with a csDMARD, and most TCs included patients receiving first-line TNFi therapy (62.7%). At baseline TNFi’s initiated included adalimumab (30.2%), golimumab (23.7%), etanercept (23.6%), infliximab (18.0%), and certolizumab (4.4%). Baseline characteristics were generally similar for the subset of 1117 TCs with a mMASES ≥ 1 at baseline, although median mMASES and BASDAI were higher and the proportion of men lower than for the larger all TC population (Table 1).
<table>
<thead>
<tr>
<th>Variable</th>
<th>All TC (n = 1668 TCs)</th>
<th>All TC with mMASES ≥ 1 at baseline (n = 1117)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years), median (IQR)</td>
<td>42 (33–51)</td>
<td>43 (34–51)</td>
</tr>
<tr>
<td>Men, n (%)</td>
<td>886 (53.1)</td>
<td>531 (47.5)</td>
</tr>
<tr>
<td>BMI, median (IQR)</td>
<td>25.3 (22.5–28.6)</td>
<td>25.7 (22.8–29.3)</td>
</tr>
<tr>
<td></td>
<td>n = 1408</td>
<td>n = 932</td>
</tr>
<tr>
<td>Disease duration (years), median (IQR)</td>
<td>9 (4–18)</td>
<td>9 (4–17)</td>
</tr>
<tr>
<td></td>
<td>n = 1633</td>
<td>n = 1092</td>
</tr>
<tr>
<td>HLA-B27+, n (%)</td>
<td>984 (65.7)</td>
<td>617 (61.5)</td>
</tr>
<tr>
<td></td>
<td>n = 1498</td>
<td>n = 1003</td>
</tr>
<tr>
<td>ASAS axial SpA criteria positive, n (%)*</td>
<td>1158 (76.4)</td>
<td>764 (76.2)</td>
</tr>
<tr>
<td></td>
<td>n = 1515</td>
<td>n = 1003</td>
</tr>
<tr>
<td>Enthesitis (mMASES &gt; 0) at baseline, n (%)</td>
<td>1117 (67.0)</td>
<td>1117 (100)</td>
</tr>
<tr>
<td>mMASES, median (IQR)</td>
<td>2 (0–4)</td>
<td>3 (2–6)</td>
</tr>
<tr>
<td>Elevated CRP, n (%)</td>
<td>987 (60.1)</td>
<td>641 (58.4)</td>
</tr>
<tr>
<td></td>
<td>n = 1642</td>
<td>n = 1098</td>
</tr>
<tr>
<td>ASDAS-CRP†, median (IQR)</td>
<td>3.3 (2.6–3.9)</td>
<td>3.4 (2.8–4.0)</td>
</tr>
<tr>
<td></td>
<td>n = 1220</td>
<td>n = 816</td>
</tr>
<tr>
<td>BASDAI score‡, median (IQR)</td>
<td>5.7 (4.1–7.0)</td>
<td>6.1 (4.7–7.3)</td>
</tr>
<tr>
<td></td>
<td>n = 1337</td>
<td>n = 889</td>
</tr>
<tr>
<td>Ever experienced uveitis, n (%)</td>
<td>258 (16.5)</td>
<td>146 (13.9)</td>
</tr>
<tr>
<td></td>
<td>n = 1567</td>
<td>n = 1054</td>
</tr>
<tr>
<td>Ever experienced arthritis, n (%)</td>
<td>963 (57.7)</td>
<td>707 (63.3)</td>
</tr>
<tr>
<td>Ever experienced dactylitis, n (%)</td>
<td>214 (12.9)</td>
<td>168 (15.3)</td>
</tr>
<tr>
<td></td>
<td>n = 1655</td>
<td>n = 1108</td>
</tr>
<tr>
<td>Ever experienced enthesitis at the heel, n (%)</td>
<td>745 (69.5)</td>
<td>625 (73.0)</td>
</tr>
<tr>
<td></td>
<td>n = 1072</td>
<td>N = 856</td>
</tr>
</tbody>
</table>
Regarding TNFi TCs for patients with active enthesitis at baseline (n = 1117) and available enthesitis assessments at 6 months (n = 404) or 12 months (n = 698), a reduction in mMASES was experienced by 72% and 70%, respectively. Score distributions at baseline and at the 6- and 12-month time points are presented in Figs. 2A and 2B. Similar findings were observed in the first TNFi TC subgroup (data not shown). Mean mMASES (SD) decreased from 2.9 (3.2) at baseline to 1.9 (2.8) at 6 months and to 1.8 (2.8) at 12 months in the all TC group and from 2.8 (3.0) at baseline to 1.6 (2.5) at 6 months and to 1.5 (2.7) at 12 months in the first TNFi subgroup.

Complete resolution of enthesitis (mMASES = 0) was observed in 37.9% of patients at 6 months and in 43.0% of patients at 12 months in the group including all TCs, compared with 40.7% and 50.9%, respectively in the first TNFi subgroup (Table 2).
<table>
<thead>
<tr>
<th>n/N (%)</th>
<th>All Treatment Courses</th>
<th>First TNFi Treatment Courses</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>At 6 months</td>
<td>153/404 (37.9)</td>
</tr>
<tr>
<td></td>
<td>At 12 months</td>
<td>300/698 (43.0)</td>
</tr>
</tbody>
</table>

\*mMASES = 0.

\†mMASES ≥ 1.

mMASES, Maastricht ankylosing spondylitis enthesitis score (modified to include the plantar fascia); TNFi, tumor necrosis factor inhibitor.

At baseline, enthesitis was most frequently observed at the fifth lumbar spinous process and the posterior superior iliac spine and least frequently at the plantar fascia (Fig. 3). In patients with active enthesitis at baseline, there was a significant reduction from baseline to 6-month follow-up in the frequency of enthesitis at all observed sites, except for the left Achilles tendon when including all TNFi TCs (Fig. 3A), and across all sites, except for the right and left Achilles tendons and the right plantar fascia in the first TNFi subgroup (Fig. 3B). At 12-month follow-up, there was a significant reduction from baseline in the frequency of enthesitis at all observed sites in both the all TC group (Fig. 3C) and the first TNFi subgroup (Fig. 3D). Across enthesitis sites evaluated, enthesitis resolved in 60.3% – 77%, while new incident enthesitis occurred in 4.0–13.5% of all TNFi TCs at 12 months (Fig. 4). Incident enthesitis, like baseline enthesitis, most frequently occurred at the posterior superior iliac spine and the fifth lumbar spinous process, whereas incident enthesitis least frequently occurred at the plantar fascia, the anterior iliac crest, and the Achilles tendon.

At the 12-month follow-up, younger age and lower mMASES at baseline were predictors of complete enthesitis resolution, while female sex and second- or later-line TNFi treatment were associated with persistence of enthesitis at 12 months in the MICE pooled estimates (Fig. 5). Negative Assessment of Spondylarthropathy international Society (ASAS) classification criteria status at baseline showed a trend favoring enthesitis resolution ($P = 0.06$). Conversely, no evidence of an association was found between resolution of enthesitis and disease duration at baseline, body mass index, or ASDAS-CRP score at baseline.

The MICE pooled estimates at 6 months in 404 TNFi TCs were similar with younger age, lower mMASES, and negative ASAS classification criteria status (OR = 3.0, 95% CI 1.49–6.04; $P < 0.01$) at baseline associated with the resolution of enthesitis, while female sex was associated with the persistence of enthesitis (data not shown).

**Discussion**
Although many clinical trials have supported the use of TNFi's for the treatment of enthesitis,[22, 23, 30] the effectiveness of TNFi's for enthesitis in patients with axSpA in a real-world setting is largely unknown. In this analysis of real-world axSpA patients using data from the SCQM registry, we demonstrate that the mMASES decreased in 72% and 70% of patients at the 6- and 12-month time points, respectively. Complete resolution of enthesitis (mMASES = 0) occurred in 37.9% and 43.0% of all TCs at 6 and 12 months, respectively, and in 40.7% and 50.9% of first TNFi TCs at 6 and 12 months, respectively. A possible explanation for the difference between 6 and 12 months could be that longer TNFi treatment leads to a better response; however, no conclusive evidence supporting this hypothesis was found in our analyses. Overall, in this axSpA patient population, a significant decrease in the frequency of enthesitis involvement was observed at all mMASES sites after 12 months, suggesting the real-world effectiveness of TNFi for the treatment of enthesitis.

It is interesting to note the differences in the improvement of site-specific enthesitis from baseline to 6 months and baseline to 12 months, whereby a significant improvement from baseline to 6 months was observed at all sites, except the Achilles tendon and the plantar fascia, which was particularly evident for the subgroup with a first TNFi. In contrast, all entheseal sites, including the Achilles tendon and the plantar fascia, demonstrated significant improvement from baseline to 12 months. This suggests that other factors, such as weight-bearing activities and higher mechanical stress at the entheses around the ankle, may lead to the requirement for a longer period of TNF inhibition in order to see a significant clinical improvement.

Data on incident enthesitis in SpA patients is very limited and largely restricted to patients with psoriatic arthritis. In patients with peripheral SpA included in the ABILITY-2 trial, 3.6% of patients treated with adalimumab presented new-onset enthesitis of the Achilles tendon at 12 weeks,[18] which is similar to the rate of 5.3% in our population of axial SpA. Conversely, a significantly higher proportion of patients (10.9%) in the placebo group presented new-onset enthesitis at the Achilles tendon in ABILITY-2.[18] New-onset enthesitis at the insertion of the plantar fascia was observed in 4.8% of treated patients in the ABILITY-2 trial (and in 8.7% of the placebo group), [18] which once again is very similar to the rate of 4.1% in our population. The higher rates of incident enthesitis observed at the 5th lumbar spine and the posterior superior iliac spine, may in part be a reflection of non-inflammatory processes, such as degenerative disease of the lumbar spine.

The mean mMASES in our study population of 2.9 (SD, 3.2) was somewhat lower than that generally observed in randomized trials, such as the RAPID-axSpA trial with mean MASES scores of 4.7 in radiographic-axSpA patients and 5.6 in nonradiographic-axSpA patients.[22] Nevertheless, in our cohort, there were significant reductions of mean mMASES over 12 months to 1.8 in the all TC group and to 1.5 in the first TNFi subgroup. The RAPID-axSpA trial reported resolution rates of enthesitis of 53.8–55.4% in radiographic-axSpA patients and of 47.1–49.3% in nonradiographic-axSpA patients at 24 weeks,[22] which are similar to the rates of 38–51% in our study. The RHAPSODY trial[23] reported resolution of plantar fascia enthesitis in 70.5% of patients at week 12, which is similar to the findings for our population at 12 months (resolution in 70.0–71.9% of TCs).
We demonstrate that younger age and a lower mMASES score at baseline were predictive of complete enthesitis resolution, while female sex and second- or later-line TNFi treatment were associated with the persistence of enthesitis at 12 months (Fig. 5). We are not aware of any other data in the literature with regards to predictors of enthesitis resolution in axSpA. Negative ASAS classification criteria for axSpA at baseline demonstrated a trend favoring the resolution of enthesitis ($P = 0.06$; Fig. 5).

Patients with many positive enthesitis sites may be more likely to present with concomitant fibromyalgia, and the clinical overlap of these conditions may be more frequent in women than in men with axSpA.[31, 32] AxSpA patients with concomitant fibromyalgia could be expected to respond less efficiently to TNFi. In the overall population of the current study, 47/1668 patients presented with a diagnosis of concurrent fibromyalgia, including 8 men (1.0%) and 39 women (5.0%). The rate of fibromyalgia in the subgroup with a mMASES $\geq 1$ at baseline was 3.5%. These proportions of fibromyalgia are somewhat lower than estimates in the literature that range from 4–25% in axSpA patients.[33]

This current study has a number of strengths, most importantly that it is the largest real-world study to date evaluating the effectiveness of TNFi on enthesitis in axSpA patients. While there are some data on the evolution of enthesitis in routine clinical practice following treatment with TNFi’s in both PsA and peripheral SpA, there are almost no real-world data regarding axial SpA. The fact that we utilized the MASES is also advantageous as this score has been demonstrated to perform better than the Leeds Enthesitis Index and the Spondyloarthritis Research Consortium of Canada Enthesitis Index in axial SpA. [34] In addition, we include data from both 6- and 12-month time points, which is important as enthesitis may resolve more slowly than other manifestations of axial SpA. In our manuscript we report information on both overall incident enthesitis, as well as incident enthesitis by site, which is rarely described.

One of the limitations of this analysis is that no direct control group was available, and therefore, we cannot make any definitive statements about the causal effect of TNFi treatment on enthesitis reduction or resolution. Patients included in the SCQM may be more likely to be treated with biologic agents and thus comprise a group of patients with more severe disease and may not be generalizable to all TNFi-treated patients. Furthermore, registry data are limited to the information collected at each visit, and patients may not have follow-up visits at time points of interest, making it more challenging to assess the effectiveness of treatments.

We hereby demonstrate that in a large real-world population of patients with axial SpA treated with a TNFi, a reduction in enthesitis was experienced by at least 70% of patients, while the complete resolution of enthesitis at 12 months was experienced by 43% of all TCs and by 51% of patients receiving a first TNFi. Significant reduction of enthesitis was observed at all sites at 6 months, except for the Achilles tendon and the plantar fascia, and at all sites at 12 months, suggesting that the ankle entheses may be more prone to mechanical strain and therefore require additional time for resolution. Younger age and lower mMASES score at baseline were predictors of complete enthesitis resolution, while female sex, and second- or later-line TNFi treatment were associated with the persistence of enthesitis.
Abbreviations

ASAS Assessment of SpondyloArthritis international Society

ASDAS-CRP Ankylosing Spondylitis Disease Activity Score

axSpA axial SpondyloArthritis

csDMARDs conventional synthetic disease-modifying antirheumatic drugs

IQR interquartile range

ITT intention to treat

MASES Maastricht Ankylosing Spondylitis Enthesitis Score

mMASES modified Maastricht Ankylosing Spondylitis Enthesitis Score

MICE multiple missing value imputation by chained equations

SCQM Swiss Clinical Quality Management in Rheumatic Diseases

SpA spondyloarthritis

TNFi tumor necrosis factor inhibitor

Declarations

Ethics approval and consent to participate:

Informed consent was obtained from all patients before inclusion in the SCQM registry and a regional ethics committee (CER-VD, 2019-00278) provided approval for collection of patient data from the SCQM cohort.

Consent for publication:

Not applicable

Availability of Data and Materials:

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Competing Interests:

MN has received consulting fees from AbbVie, Celgene, Eli Lilly, Novartis, and Pfizer.
AC has received consulting and/or speaking fees from AbbVie, Celgene, MSD, Eli Lilly, Novartis, and Pfizer.

RM has received honoraria and research support from AbbVie, Nordic, Pfizer, Janssen-Cilag, MSD, and Sanofi-Aventis.

PZ, MS, and FG are employees of AbbVie Inc.

BM has received honoraria from AbbVie, Celgene, Eli Lilly, Janssen-Cilag, Merck (MSD), Novartis, Pfizer, Roche, Sanofi-Aventis, and UCB.

AS and EP have no conflicts to disclose.

TH has received honoraria and research support from AbbVie, GSK, Eli Lilly, Novartis, Pfizer, Janssen-Cilag, MSD and Sanofi-Aventis.

Funding:

AbbVie supported this project financially.

Authors' contributions:

Study concept and design: All authors

Acquisition of data: MN, AC

Analysis and interpretation of data: All authors

Writing of the manuscript: MN, PZ, FG, TH, EP

Critical revision of the manuscript for important intellectual content: All authors

Statistical analysis: MN, EP, AS

Acknowledgements:

We thank the patients and rheumatologists who entered data into the SCQM. A list of participating offices and hospitals that are contributing to the SCQM registries can be found on www.scqm.ch/institutions. AbbVie supported this project financially, contributed to its design, and was involved in the collection, analysis, and interpretation of the data, and in the writing, review, and approval of the publication. All authors had access to the relevant data and participated in the drafting, review, and approval of the abstract. No honoraria or payments were made for authorship and there were no ghostwriters. Medical writing support was provided by Madhura Mehta, PhD, and Janet Matsuura, PhD, of ICON (North Wales, PA) and was funded by AbbVie.
References


27. **About Us: The basis for successful therapy** [https://www.scqm.ch/en/ueber-uns/]


Figures
Figure 1

Selection of axSpA Study Sample. Number of treatment courses for each category are shown. MASES, Maastricht ankylosing spondylitis enthesitis score; SCQM, Swiss Clinical Quality Management; TNFi, tumor necrosis factor inhibitors.
Figure 2

mMASES at Baseline and (A) 6 or (B) 12 Months. Each line on the plot connects the before and after mMASES values of a treatment course. More than one treatment course may have overlapping lines. The line colours indicate whether mMASES reduced, increased, or stayed the same. The numbers at baseline and the 6-month and 12-month time points indicate the number of TCs with the corresponding score. The black line indicates the evolution of the mean mMASES score between the 2 time points. For the
assessment of modified MASES at the 6-month time point, values in interval [6 ± 3 months] were used and at the 12-month time point, values in interval [12 ± 3 months] were used. mMASES, modified Maastricht ankylosing spondylitis enthesitis score (modified to include the plantar fascia); TC, treatment course; TNFi, tumor necrosis factor inhibitor.

Figure 3

Enthesitis Localization at Baseline and 6 (A, C) or 12 (B, D) Months. Patients had active enthesitis at baseline and received TNFi therapy. Data are presented for all TCs and for the subgroup of first TNFi TCs. P value corrected for multiplicity (using the Holm-Bonferroni method). TC, treatment course; TNFi, tumor necrosis factor inhibitor. *P<0.05, **P<0.01, and ***P<0.001.
Figure 4

Incident and Resolved Enthesitis by Location at 12 months. Enthesitis by location was assessed for all TNFi treatment courses with non-missing follow-up data at 12 months (n=1038). BL, baseline; TNFi, tumor necrosis factor inhibitors. *P<0.05, **P<0.01, and ***P<0.001.
Figure 5

Explanatory Variables of Enthesitis Resolution at 12-Month Follow-up (n=698). Logistic regression analysis for resolution of enthesitis based on multiple imputation of missing baseline covariate data. Analysis was performed with 698 treatment courses in patients who initiated TNFi and with available enthesitis assessments at 12-month follow-up. The numbers of enthesitis resolutions observed at 12-month follow-up was 300. All variables presented represent values at baseline. BMI is a categorical variable with levels defined as underweight (BMI <18.5), normal (BMI 18.5–24.9), and overweight (BMI >24.9). ASAS classification negative indicates patients not meeting ASAS criteria for axial spondyloarthritis. Predictors with 95% CIs that extend beyond the x-axis scale upper limit of 2 are indicated with an arrowhead at the end of the error bar. ASDAS-CRP, Ankylosing Spondylitis Disease Activity Score–C-reactive protein; ASAS, Assessment of SpondyloArthritis international Society; BMI, body mass index; mMASES, modified Maastricht ankylosing spondylitis enthesitis score (modified to include the plantar fascia); TNFi, tumor necrosis factor inhibitor.